EMA — authorised 21 March 2014
- Application: EMEA/H/C/002571
- Marketing authorisation holder: Endocyte Europe, B.V.
- Local brand name: Vynfinit
- Indication: Treatment of platinum resistant ovarian cancer (PROC)
- Status: withdrawn
🇪🇺 Vynfinit in European Union
EMA authorised Vynfinit on 21 March 2014
Marketing authorisation
Other Oncology approved in European Union
Frequently asked questions
Is Vynfinit approved in European Union?
Yes. EMA authorised it on 21 March 2014.
Who is the marketing authorisation holder for Vynfinit in European Union?
Endocyte Europe, B.V. holds the EU marketing authorisation.